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MET Mutation 
Associated with 
Responsiveness to 
Crizotinib
To the Editor:
Activation of c-MET oncogene 
can be the result of amplification or 
activating mutations. In this letter, 
we would like to share our experience 
of treating a patient with metastatic 
lung adenocarcinoma, whose tumor 
was found to harbor a MET mutation 
occurring at a splice site within the 
juxtamembrane domain.
A 71-year-old Caucasian man 
with a 15 pack-year smoking history 
presented to our clinic with a biopsy-
proven left lung adenocarcinoma 
with a 6.4 × 5 cm left pleural-based 
mass invading the fourth rib, left hilar 
lymphadenopathy, and numerous bilat-
eral sub-centimeter pulmonary nod-
ules. He received palliative thoracic 
radiation to a total dose of 3000 cGy, 
followed by two cycles of chemother-
apy with carboplatin AUC 5 and peme-
trexed 500 mg/m2 intravenously every 
3 weeks. Follow-up computed tomog-
raphy scan of the chest and abdomen 
revealed improvement in the previously 
irradiated left lung mass, mediasti-
nal and hilar adenopathy, but new and 
enlarging pulmonary nodules, bilateral 
supraclavicular adenopathy and new 
sclerotic bone lesions.
Ta rg e t e d   n e x t - g e n e r a t i o n 
 sequencing of 42 cancer-related genes 
(Comprehensive Cancer Gene Set ver-
sion 2 assay, GPS@WUSTL, St. Louis, 
MO) was performed on DNA derived 
from the formalin-fixed paraffin-
embedded tumor biopsy specimen.1 
A MET single nucleotide variant was 
identified, chr7:g.116412043G>C, 
involving the terminal nucleotide of 
exon 14 (Fig. 1). This variant could 
result in a p.D1028H missense muta-
tion (NM_001127500:c.3082G>C), 
but is also predicted by in-silico mod-
eling to affect the splice donor site 
(Fig. 2). Fluorescence in-situ hybrid-
ization analysis was performed using 
commercial probes (Abbott Molecular, 
Des Plaines, IL) for MET/CEP7 
(7q31.2/7p11.1-q11.1). Polysomy of 
chromosome 7 was noted (CEP7 and 
MET average copy numbers 2.31 and 
2.23, respectively), although the MET/
CEP7 ratio of 0.96 was negative for 
MET amplification. He was started on 
crizotinib 250 mg orally twice daily. 
Restaging computed tomography 
scans after 6 weeks of therapy revealed 
decrease in size of the pulmonary 
lesions with continued response at 6 
months (Fig. 3).
The MET receptor tyrosine 
kinase is a known oncogene, with a 
somatic mutation frequency of 8.3% 
in lung adenocarcinoma and 2% in 
lung squamous cell carcinoma, based 
on sequencing data from The Cancer 
Genome Atlas (TCGA).2 MET muta-
tions are seen typically in smok-
ers, and may co-occur with TP53 
mutations.3 Unlike activating EGFR 
mutations that occur primarily in 
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the tyrosine kinase domain, MET 
mutations are distributed across all 
domains of the gene. Although muta-
tions in the semaphorin domain may 
affect ligand-binding affinity, juxta-
membrane domain mutations impact 
CBL-mediated ubiquitination and 
MET receptor degradation. Somatic 
splice site mutations involving MET 
exon 14, resulting in deletion of the 
juxtamembrane domain, have been 
described in lung cancer.4,5 The juxta-
membrane domain contains a binding 
site for CBL, which is required for 
ubiquitin-mediated MET degrada-
tion. The variant described here could 
result in over-activation of MET via 
skipping of exon 14 with loss of the 
CBL/ubiquitin-mediated degradation 
(Fig. 2). To the best of our knowledge, 
this is the first report demonstrating 
successful targeting of this MET tyro-
sine kinase variant by crizotinib.
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FIGURE 1. MET chr7:g.116412043G>C alteration as viewed in the Integrative Genomics Viewer (Broad Institute, Cambridge, 
MA). The guanine to cytosine alteration is highlighted at the terminus of MET exon 14.
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FIGURE 2. MET alteration and predicted outcomes. Each panel shows MET exon 14 and flanking DNA sequence with splicing 
events indicated by black lines followed by the resulting protein sequence. A, Normal MET sequence and splicing. The c-Cbl bind-
ing site (Y1021) is marked with a box. B, Effect of chr7:g.116412043G>C alteration (red, arrow) if splicing is unimpaired resulting 
in a p.D1028H substitution without deletion of exon 14. C, Alternately, as predicted by splice site algorithms, the variant could 
result in altered splicing with deletion of exon 14, as has been described for other MET splice site variants in lung cancer.
FIGURE 3. Radiographic response to crizotinib. CT scans (A) at baseline and (B) after 6 weeks and (C) 6 months of crizotinib. 
CT, computed tomography.
